Royal Philips: Philips to become a global leader in patient care management solutions for the hospital and the home through the acquisition of BioTelemetry, Inc.
USD 72.00 per share; implied enterprise value of USD 2.8 billion (approx. EUR 2.3 billion)
Acquisition is a strong fit with Philips strategy to transform the delivery of healthcare: combination of Philips leading patient monitoring position in the hospital with BioTelemetry s leading cardiac diagnostics and monitoring position outside the hospital
With 2019 sales of USD 439 million, BioTelemetry
annually monitors over 1 million cardiac patients remotely; its portfolio includes wearable heart monitors,
AI-based data analytics and services
C
eographical expansion, portfolio innovation synergies
Philips to Become a Global Leader in Patient Care Management Solutions for the Hospital and the Home Through the Acquisition of BioTelemetry, Inc
koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.
Philips to Acquire BioTelemetry - MarketWatch
marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.
[December 17, 2020]
Mesoblast Update on COVID-19 ARDS Trial
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today provided an update on the randomized controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection after the Data Safety Monitoring Board (DSMB) performed a third interim analysis on the trialâs first 180 patients. The trial was powered to achieve a primary endpoint of 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of maximal care in a trial of 300 patients. This projected mortality reduction was based on pilot data observed during the initial stages of the pandemic when control mortality rates were exceedingly high and prior to new evolving treatment regimens that have reduced disease mortality in ventilated patients. The DSMB reported that there were no safety concerns and noted that the trial is not
State Enforcers Expanding Premerger and Antitrust Jurisdiction Over Healthcare Transactions: Guidance for This Growing Trend
By Barbara Sicalides, Esq., Daniel Anziska, Esq., Megan Morley, Esq. and Dennie Zastrow, Esq.,
Troutman Pepper Hamilton Sanders, LLP, Philadelphia, PA Share:
Given the importance and rising costs of healthcare as well as a concern about whether federal authorities have the same interests and incentives to enforce the antitrust laws, recently states have taken actions to be better informed about, challenge, or prevent healthcare affiliations. For example, Connecticut and Washington enacted and California has proposed legislation requiring premerger notification to their respective state attorney general offices of certain healthcare-related deals before consummation. These states can then use the information gathered from these notifications for their investigative and enforcement functions – possibly challenging the transactions. Notably, unli